MedTrace Logo

Pemetrexed and S-1 in Combination With Bevacizumab in Refractory Colorectal Cancer

NCT03843853 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2022-07-25

No results posted yet for this study

Summary

Limited agents are optional after standard first and second line treatment for mCRC. Only Regorafenib and Fruquintinib are approved in China. PFS of these targeted drugs are not very long. Pemetrexed has shown significant efficacy in advanced lung cancer regarding PFS and OS with controllable toxicity. S-1 has been used in colorectal cancer with promising outcomes. Bevacizumab is also an important monoclonal antibody which could make benefits in treated patients. This study is aimed to explore the efficacy, safety in advanced colorectal cancer failed to standard therapy in Chinese population.

Conditions

  • Colorectal Neoplasms

Interventions

DRUG

Pemetrexed

Pemetrexed 500 mg/m2 d1

DRUG

S-1

S-1 (20mg、25mg), capsule, 40\~60mg, Bid,p.o, d1\~14

DRUG

Bevacizumab

Bevacizumab 7.5 mg/kg d1

Sponsors & Collaborators

  • Jiangsu HanSoh Tharmaceutical Group Co., Ltd

    collaborator UNKNOWN

  • The First Affiliated Hospital with Nanjing Medical University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-01
Primary Completion
2021-11-01
Completion
2022-05-01
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03843853 on ClinicalTrials.gov